CorMedix
CRMD
129 hedge funds and large institutions have $186M invested in CorMedix in 2024 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 50 increasing their positions, 23 reducing their positions, and 11 closing their positions.
264% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 11
117% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 23
66% more call options, than puts
Call options by funds: $6.63M | Put options by funds: $4M
26% more funds holding
Funds holding: 102 → 129 (+27)
20% more capital invested
Capital invested by funds: $155M → $186M (+$31.4M)
3.55% more ownership
Funds ownership: 34.28% → 37.83% (+3.6%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EIM
Elliott Investment Management
West Palm Beach,
Florida
|
+$13.2M |
| 2 |
FTM
First Turn Management
Del Mar,
California
|
+$10.2M |
| 3 |
BlackRock
New York
|
+$9.1M |
| 4 |
PIP
Palisades Investment Partners
Santa Monica,
California
|
+$3.64M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$14.7M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
-$7.21M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.96M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$1.31M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$1.05M |
CRMD Hedge Fund Activity: Q4 2024 in Review
129 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q4 2024, worth a combined $186M — up 20% from $155M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new CRMD positions and 11 closed out — a net gain of 29 holders — while 50 added to existing stakes and 23 trimmed.
The largest buyer was Elliott Investment Management, adding an estimated $13.2M. The largest seller was Rosalind Advisors, exiting entirely with an estimated $14.7M sold.
- 129 institutional investors held CorMedix (CRMD) as of Q4 2024, up from 102 in Q3 2024.
- Funds reported $186M of CorMedix stock for Q4 2024, up 20% quarter-over-quarter.
- 40 funds opened new CorMedix positions in Q4 2024 and 11 closed out, a net change of +29 holders.
- The largest CorMedix buyer in Q4 2024 was Elliott Investment Management, an estimated $13.2M added.
- The largest CorMedix seller in Q4 2024 was Rosalind Advisors, an estimated $14.7M sold.
Based on aggregated 13F filings for Q4 2024.